OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) has an important role in bridging patients to lung transplantation. In this study, we present our experience with pretransplant ECMO during the last 7 years and investigate its impact on graft outcomes.
Extracorporeal membrane oxygenation as a bridge to lung transplantation may not impact overall mortality risk after transplantation: results from a 7-year single-centre experience † 
INTRODUCTION
Before lung transplantation, bridging strategies include invasive or non-invasive mechanical ventilation and venovenous (v-v) or venoarterial (v-a) extracorporeal membrane oxygenation (ECMO) [1] . Recently, many case series have reported encouraging results of bridging patients to lung transplantation with ECMO, especially if an 'awake' strategy was used [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . However, pretransplant ECMO support has been associated with major complications and increased in-hospital mortality and costs [8, 12] . Therefore, concerns about bridging severely decompensated patients to lung transplantation remain.
Previously, in a 2012 study on the experience of our institution with pretransplant ECMO, we demonstrated the superiority of awake ECMO over invasive mechanical ventilation [3] . In 2010, we developed a protocol integrating pre-, intra-and postoperative extended ECMO support in patients undergoing lung transplantation requiring cardiopulmonary support [13] [14] [15] .
In this study, we present our accumulated experience with ECMO as a bridge to lung transplantation in patients transplanted since 2010 and investigated its impact on graft survival at follow-up. †Presented at the 31st Annual Meeting of the European Association for CardioThoracic Surgery, Vienna, Austria, 7-11 October 2017. ‡ The first two authors contributed equally to this study.
METHODS

Patients and variable definition
A retrospective study was performed in a single university centre, including all patients who underwent lung transplantation between January 2010 and April 2017. The patients who required ECMO as a bridge to transplantation formed the pretransplant (pre-Tx) ECMO+ group and the patients who did not require ECMO formed the pre-Tx ECMO-group. Of the pre-Tx ECMO+ patients who died while waiting for a suitable donor, only a basic set of data was available. Nevertheless, their characteristics were reported in the Results section.
Patient records and outpatient visits were retrospectively reviewed. Follow-up was 100% complete and ended on 1 August 2017. Median (1st-3rd quartiles) and mean (standard deviation) follow-up was 35 (16-55) and 37 (25) months, respectively, and amounted to 211 and 2622 patient-years for pre-Tx ECMO+ and ECMO-patients, respectively. Follow-up time did not differ between pre-Tx ECMO+ and pre-Tx ECMO-patients (P = 0.93).
The hospital ethics review board, considering a retrospective study, waived the need for patient consent for the study.
Graft survival was defined as the combined freedom from patient mortality and retransplant. The variables primary graft dysfunction, chronic lung allograft rejection, pulsed-steroid therapy and biopsy-confirmed acute rejections have been defined elsewhere [14] [15] [16] [17] [18] .
Management of patients who required pretransplant extracorporeal membrane oxygenation patients
There were 2 categories of patients who were potential candidates for ECMO support as a bridge to lung transplantation. The 1st category included patients who had already been listed for lung transplantation but had developed respiratory and/or haemodynamic deterioration during the waiting time, thus requiring gas exchange and/or cardiopulmonary support until lung transplantation. The 2nd category of patients included those who had been transferred to our multidisciplinary intensive care unit (ICU) from a peripheral hospital, needed ECMO support, but due to irreversible respiratory failure, an ECMO weaning was not foreseeable and lung transplantation remained the sole therapeutic option. In both categories, decision to definitively proceed to lung transplantation was always discussed by a multidisciplinary team including an adult and paediatric pulmonologist and a cardiothoracic surgeon. A risk-to-benefit balance for proceeding to transplantation was based on patient age, underlying lung pathology, comorbidities, neurological status, vasopressor requirement and the presence and reversibility of concomitant organ dysfunction, such as liver and renal failure.
An 'awake' ECMO strategy was used whenever possible [2, 3] . In patients with a primary respiratory decompensation, awake v-v ECMO was used to avoid sedation and invasive mechanical ventilation support to preserve their respiratory musculature and active mobilization. If invasive mechanical ventilation was required before or after ECMO implantation, its duration was usually kept to a minimum. If prompt extubation was not possible, a tracheostomy was usually performed, and aggressive ventilator weaning was pursued. Similarly, in those patients with a primary haemodynamic decompensation, v-a ECMO was implanted before secondary organ dysfunction ensued.
Since 2010, ECMO as a bridge to transplantation was included in an ECMO protocol that integrated pre-, intra-and postoperative extended ECMO support [13] [14] [15] .
Statistics
Data collection and analyses were performed retrospectively using SPSS 24.0 (IBM, Armonk, NY, USA), according to the last EJCTS/ICVTS guidelines [19] . Primary end-points were in-hospital mortality and graft survival. Secondary end-points were freedom from biopsy-confirmed acute rejection, pulsed-steroid therapy, chronic lung allograft rejection and retransplant. Categorical and continuous variables were summarized as counts and percentages and median (1st-3rd quartiles) or mean (SD), respectively. The independent-samples non-parametric Mann-Whitney test and the v 2 -test or the Fisher's exact test, in case of cells with count lower than 5, were used for group comparisons of continuous and categorical variables, respectively.
Survival estimates along with freedom from other end-points were calculated by the product-limit method of Kaplan-Meier. Differences among groups were quantified using the log-rank test. The pre-TX ECMO+ patients who did not survive until lung transplantation were not considered in subsequent analyses comparing post-transplant outcomes.
A binary logistic regression analysis was used to find independent risk factors of in-hospital mortality among pre-Tx ECMO+ patients and the overall study population. Model calibration was evaluated using the Hosmer-Lemeshow test for goodness of fit. A Cox regression analysis was performed to identify the independent risk factors for graft mortality. The proportional hazards assumption was tested using the complementary log-log KaplanMeier plots and including the time-dependent coefficients into the regression model.
Variables with a P-value <0.15 at the univariable analysis were entered in the regression models. Only pretransplant and intraoperative donor and recipient variables were considered (Tables 1  and 2 ). In particular, in the analysis of risk factors for in-hospital mortality among pre-Tx ECMO+ patients, other variables were included, such as the need for dialysis, creatinine values and liver function parameters, which are not reported in Tables 1 and 2 . Results were reported as odds ratios for the binary logistic regression analysis and as hazard ratios for the Cox regression, with a 95% confidence interval and corresponding P-value.
Two-tailed P-values < _0.05 were considered significant.
RESULTS
Patients who required pretransplant extracorporeal membrane oxygenation
Between January 2010 and April 2017, among the 917 patients undergoing lung transplantation at our institution, 68 (7%) patients were successfully bridged to transplantation using ECMO (pre-Tx ECMO+ patients). The remaining 849 (93%) patients did not require pre-Tx ECMO (pre-Tx ECMO-patients).
During the same period, 19 patients required ECMO as a bridge to transplantation, but died before transplantation, after a median support time of 9 (4-14) days. Death was due to bleeding (cerebral, n = 4; other, n = 2), acute haemodynamic decompensation (cardiopulmonary resuscitation, n = 2; right heart failure n = 6), sepsis (n = 4) or massive haemolysis (n = 1). There was no significant difference between pre-Tx ECMO+ patients dying before, or surviving to, transplantation regarding female gender (P = 0.73), age (P = 0.28), indication for transplantation [cystic fibrosis, P = 0.90; lung fibrosis, P = 0.080; pulmonary artery hypertension (PAH), P = 0.72; retransplant, P = 0.19], ECMO modality (v-v, P = 0.54; v-a, P = 0.39) or support time (P = 0.46). Pre-Tx ECMO+ patients not surviving to transplantation more frequently showed acute kidney failure requiring haemodialysis during bridging (37% vs 9%, P = 0.006).
Supplementary Material, Fig. S1 shows the yearly number of preTx ECMO+ patients as a percentage of all lung transplantations. Median support time during the study period was 9 (5-16) days. ECMO was implanted for a primary hypoxic or hypercapnic respiratory failure in 50 (74%) patients and for a primary haemodynamic decompensation in 18 (36%) patients. Among the pre-Tx ECMO+ patients, 40 (59%) patients had already been listed for transplantation before ECMO implantation, 23 (34%) required invasive mechanical ventilation (16 patients before and 7 patients after ECMO implantation), 19 (28%) required a tracheostomy and 6 (9%) required haemodialysis treatment during bridging. V-v and v-a ECMO were used in 50 (74%) and 25 (37%) patients, respectively, with 7 patients undergoing a switch from v-v to v-a ECMO (v-v to arterial ECMO in 3 patients) (Fig. 1) , due to cardiopulmonary reanimation (n = 1), right ventricular failure (n = 3), right heart failure with upper body deoxygenation (n = 1) and poor oxygenation notwithstanding v-v ECMO (n = 2).
An awake ECMO strategy was successfully applied in 57 (84%) patients. In the remaining 11 (16%) patients, continuous sedation and invasive mechanical ventilation were necessary due to recurrent intrabronchial bleeding (n = 3), haemodynamic instability (n = 3), poor oxygenation (n = 3) and neurological agitation and incompliance (n = 2).
Pre-, intra-and postoperative characteristics of patients who required pretransplant extracorporeal membrane oxygenation and patients who did not require pretransplant extracorporeal membrane oxygenation Pre-Tx ECMO+ patients were younger (16% children) but showed a higher preoperative risk profile than pre-Tx ECMO-patients, with a higher prevalence of PAH, retransplant and, expectedly, the need for invasive mechanical ventilation and ICU stay. Retransplants were performed at a median of 46 (27-78) months after the 1st transplant (Tables 1 and 2) .
Intraoperatively, 11 (16%) pre-TX ECMO+ patients required switching from v-v to v-a ECMO due to haemodynamic instability (Fig. 1) . The requirement for blood products was also higher in pre-Tx ECMO+ than ECMO-patients (Table 2) . Postoperatively, pre-Tx ECMO+ patients showed a higher prevalence of major complications, a higher requirement for blood products and longer mechanical ventilation, ICU and hospital stay times than pre-Tx ECMO-patients (Table 3) .
In-hospital mortality was higher in pre-Tx ECMO+ than pre-Tx ECMO-patients (P = 0.003). If only pre-Tx ECMO+ patients were considered, among pretransplant variables, only the need for haemodialysis at any time during bridging was identified as a risk factor for in-hospital mortality after lung transplantation (Table 4) . Median values of liver enzymes (aspartate transaminase and alanine transaminase) and creatinine during ECMO support were not associated with in-hospital mortality (P = 0.20, 0.93 and 0.22, respectively). In-hospital mortality of pre-Tx ECMO+ patients was equal in preoperatively listed (n = 5) or unevaluated (n = 5) candidates (P = 0.73).
Outcomes at follow-up
At the Cox analysis, ECMO as a bridge to transplantation did not emerge as a risk factor for graft survival (Table 5) .
Outcomes at follow-up did not differ between groups. In particular, in the case of graft and overall patient survival, the initial attrition related to higher in-hospital mortality diminished over time (Table 6 and Fig. 2) . If only adult patients were considered, graft survival was lower in pre-Tx ECMO+ than pre-Tx ECMOpatients (Supplementary Material, Tables S1 and S2). However, survival conditioned to hospital discharge did not differ between groups before and after age stratification.
In pre-Tx ECMO+ patients, outcomes did not differ between patients who underwent an awake ECMO strategy and those who did not (graft survival, P = 0.38; patient survival, P = 0.25; freedom from biopsy-confirmed rejection, pulsed-steroid therapy, chronic lung allograft rejection and retransplant, P = 0.53, 0.98, 0.58 and 0.46, respectively). If all 87 pre-Tx ECMO+ patients were considered in an intention-to-treat analysis, 1-year and 5-year survivals (%) from ECMO implant time were 63 (SD 5) and 52 (SD 6).
At 1 year follow-up, forced expiratory volume in 1 s (FEV 1 , % predicted) was lower in pre-Tx ECMO+ than pre-Tx ECMOpatients (median value 72% vs 88%, respectively, P < 0.001).
DISCUSSION
The results of this study confirmed that ECMO is essential for successfully bridging respiratory and haemodynamic decompensated patients to lung transplantation. Although a patient on ECMO listed for lung transplantation in our cohort had an overall in-hospital mortality risk of approximately 33%, once transplanted, the remaining risk of in-hospital mortality is only 10% higher than for pre-Tx ECMO-patients.
During the last decade, few studies on pretransplant ECMO focused on comparing graft survival between pre-Tx ECMO+ and pre-Tx ECMO-patients [4] [5] [6] [7] 9] . This is a crucial point, because it could be argued that due to the ever-present donor organ shortage, it would not be sensible to transplant severely respiratory and haemodynamic decompensated patients. Toyoda et al. [4] showed no survival difference between pre-Tx ECMO+ (n = 24) and pre-Tx ECMO-(n = 691) patients (at 1 year 74% vs 83%, P = 0.787). Moreover, Lang et al. [5] showed no survival difference between retransplanted patients with preoperative awake ECMO (n = 5) or patients without any bridging (n = 23) (at 1 year, 60% vs 70%). Schechter et al. [9] showed that 1-year survival was not different between patients bridged only with ECMO compared with control patients (70.4% vs 84.2%). On the contrary, Inci et al. [7] showed worse overall and 3-month conditional survivals in preTx ECMO+ (n = 26) vs pre-Tx ECMO-(n = 160) patients (68% vs 85%, P = 0.001; 86% vs 92%, P = 0.03, respectively). In this study, although pre-Tx ECMO+ patients showed lower FEV 1 values at 1 year, freedom from acute and chronic rejection was not different between groups. Consequently, we deem ECMO bridging to lung transplantation to be justified, and it should, therefore, not be denied a priori to severely ill patients. Moreover, careful multidisciplinary evaluation of non-listed patients had allowed equivalent postoperative survival when compared with listed patients. ECMO-bridged patients in our study were younger than control patients, with cystic fibrosis and PAH patients being over-represented. Denying ECMO bridging to these young patients may not be ethically acceptable. However, ECMO therapy is not devoid of complications. Pre-Tx ECMO+ patients showed a higher prevalence of perioperative major complications, such as primary graft dysfunction, bleeding and haemodialysis, required more blood products and more frequently a tracheostomy, thus staying longer at the ICU and in hospital (Table 3) .
We have introduced several management principles that are fundamental to improving ECMO bridging results and may explain the decrease of pre-Tx ECMO prevalence during the study period. First, the presence of multiorgan failure is a clear contraindication to bridging. In this study, we demonstrated that kidney failure with the need for haemodialysis at any time during bridging increases in-hospital mortality. However, renal failure is more frequently an epiphenomenon of the underlying disease severity. Thus, each patient on dialysis is carefully evaluated for concomitant organ dysfunction and the reversibility of renal damage. Other risk factors for bridging failure have been recently reported [20] . Second, patients already listed for transplantation are ideal candidates for bridging. In these patients, we prefer implanting ECMO before irreversible respiratory and haemodynamic decompensation develops. Conversely, those patients who are not listed for transplantation and are transferred to our multidisciplinary ICU from a peripheral hospital more frequently are already on mechanical ventilation and are more severely decompensated. Third, although transplant diagnosis has no influence on the bridging decision, patients requiring retransplantation and patients with lung fibrosis may represent a higher risk population due to the associated comorbidities and more advanced age, in comparison with patients with cystic fibrosis and PAH. Our results, however, and those of other authors, demonstrate the contrary [5] . We usually do not proceed to transplanting these older patients if they require invasive mechanical ventilation while on ECMO. Fourth, an awake ECMO strategy should be applied whenever possible. The benefits of reducing mechanical ventilation times and of early patient mobilization have been previously demonstrated [2, 3, 10] . Fifth, careful attention to prevent bleeding is of paramount importance. We usually correct any alteration of coagulation factors aggressively and pay particular attention to the intraoperative haemostasis. Finally, the application of our ECMO protocol has allowed safe transplantation of high-risk patients such as those with PAH [15] . Application of the ECMO protocol along with close patient monitoring during the first hours after transplantation, negative fluid balance and control of arterial blood pressure may explain the lack of primary graft dysfunction impact on long-term survival in our pre-ECMO+ patients.
Limitations
The retrospective design of this study introduced several biases, but a randomized trial comparing bridging strategies is not ethically feasible. The higher percentage of paediatric patients in the pre-Tx ECMO+ than in the pre-Tx ECMO-group, which was related to the different transplant indications, positively influenced graft survival in the former group. Moreover, a Type 2 error, due to the low number of patients in the pre-Tx ECMO+ group, may have confounded the survival results. However, the only chance of increasing the number of case patients is to resort to a retrospective registry analysis, which has biases itself.
Patients who died on ECMO while waiting for transplantation were excluded, because we focused this study on the impact of ECMO bridging on graft survival, and thus only transplanted patients were included.
We excluded our earlier experience (2006-2010) with pretransplant ECMO because it had been already partly published elsewhere [2] and, since 2010, our ECMO protocols and our candidate selection have markedly changed.
CONCLUSIONS
Although complications and in-hospital mortality were significantly elevated, pretransplant ECMO as a bridge to transplantation resulted in acceptable early outcomes and may not impact graft survival in the long term.
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